<DOC>
	<DOCNO>NCT00127881</DOCNO>
	<brief_summary>The purpose study determine efficacy drug , HuMax-CD4 , patient mycosis fungoides ( MF ) sezary syndrome intolerant respond treatment Targretin速 one standard therapy .</brief_summary>
	<brief_title>Study Human Monoclonal Antibody Treat Mycosis Fungoides Sezary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>A biopsy compatible diagnosis MF sezary syndrome CD4 positive phenotype within 6 month study entry Refractory intolerant least two prior therapy , one Targretin速 ( combination hereof ) . Signed informed consent Prior treatment Total Skin Electron Beam ( TSEB ) therapy within six month Prior treatment Campath ( alemtuzumab ) Prior treatment three regimen single agent chemotherapy Prior treatment pentostatin within 6 month Treatment within 4 week prior visit 2 topical Targretin速 , skin direct therapy systemic anticancer therapy , , limit : Targretin速 , UVlight therapy , local Electron Beam Therapy ( EBT ) , extracorporal photo chemotherapy , methotrexate , bleomycin , cyclophosphamide , combination chemotherapy , oral retinoids , systemic glucocorticosteroids , carmustine , nitrogen mustard , systemic vitamin A etretinate Treatment topical glucocorticosteroids within 2 week prior visit 2 Unwillingness inability avoid prolonged exposure sun UV light sufficient produce mild erythema think investigator likely modify patient 's disease Concurrent previous malignancy within past five year except adequately treat situ carcinoma uterine cervix basal squamous cell skin carcinoma Significant concurrent , uncontrolled , active medical condition include , limited renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral psychiatric disease Known suspect positive serology HIV Known suspect positive serology hepatitis B C Patients currently participate trial receive treatment experimental agent within 4 week prior visit 1 ( screen ) Prior treatment antiCD4 monoclonal antibody Breast feed woman woman positive pregnancy test Visit 1 Women childbearing potential willing use either hormonal birth control , intrauterine device doublebarrier method entire study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Refractory intolerant Mycosis Fungoides sezary syndrome</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>To evaluate efficacy safety zanolimumab Mycosis Fungoides sezary syndrome</keyword>
</DOC>